Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer
Learn more about:
Related Clinical Trial
Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue
Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
Natural Progesterone for the Treatment of Recurrent Glioblastoma
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine®) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
A Phase I/II Study of Pembrolizumab and M032 (NSC 733972)
Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma
Engineered NK Cells Containing Deleted TGF-BetaR2 and NR3C1 for the Treatment of Recurrent Glioblastoma
ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma
Phase II Trial Evaluating the Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients
Nedisertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma
Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel for Recurrent Glioblastoma
Mycophenolate Mofetil Combined With Radiation Therapy in Recurrent Glioblastoma
Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma
131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma
Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG
Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
Oncolytic Adenovirus DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma
Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme
Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas
A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas
A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII
INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma
AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme
Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme
Neoadjuvant and Adjuvant Fenretinide Compared With Adjuvant Fenretinide Alone in Treating Patients Who Are Undergoing Surgical Resection For Recurrent Glioblastoma Multiforme
CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme
BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab
Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme
Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
Pazopanib in Treating Patients With Recurrent Glioblastoma
Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma
GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
Lonafarnib and Temozolomide in Treating Patients With Glioblastoma Multiforme That Is Recurrent or Did Not Respond to Previous Treatment With Temozolomide
NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma
Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED)
EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme
Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
Bevacizumab Beyond Progression (BBP)
Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)
Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Oxaliplatin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme
Carboxyamidotriazole + RT in Treating Patients Newly Diagnosed Supratentorial GBM
Vaccine Therapy in Treating Patients With Recurrent Glioblastoma
Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme
Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma
Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM)
Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma
Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma
Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer
Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy
Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas
Pembrolizumab in Treating Patients With Recurrent Glioblastoma
GW572016 to Treat Recurrent Malignant Brain Tumors
Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma
Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas
Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma
Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM
Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma
Dose-Intense Temozolomide in Recurrent Glioblastoma
Evaluate the Safety and Effectiveness of Intranasal Administration of Temozolomide in Patients With Glioblastoma
Partial Brain Radiation Therapy, Temozolomide, Chloroquine, and Tumor Treating Fields Therapy for the Treatment of Newly Diagnosed Glioblastoma
Multi-site Validation and Application of a Consensus DSC-MRI Protocol
Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification
SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma
Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma
Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme
Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma
Pilot Study Using Amide Proton Transfer Magnetic Resonance Imaging Distinguishing Glioma
DSC-MRI in Measuring Relative Cerebral Blood Volume for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas
Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM
Ph II Bevacizumab + Etoposide for Pts w Recurrent MG
Ph I Dasatinib + Erlotinib in Recurrent MG
Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma
Radiosurgery Plus Bevacizumab in Glioblastoma
Hyperbaric Hyperoxygenation With Radiotherapy and Temozolomide in Adults With Newly Diagnosed Glioblastoma
Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)
Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)
Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG
Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan
ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
AMG 102 and Avastin for Recurrent Malignant Glioma
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme
Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma
A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma
Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme
Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme
Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors
Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma
Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas
Phase 1/2 Study in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients
Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors
Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma
NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery
Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma
Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas
Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma
Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma